Study #2016-0170
Lymphatic and Systemic Immunity Changes in Post-Radiation Lymphedema
MD Anderson Study Status
Not Accepting
Treatment Agent
Indocyanine Green (ICG)
Description
The goal of this study is to find out which immune molecules, cells, and genes are involved in the development of lymphedema (LE), so that medicines that target them can be considered for treating lymphedema. The hypothesis is that LE is a systemic, autoimmune-like disease that is initiated by inflammatory cytokines induced by surgery, radiation, and possibly chemotherapy in genetically susceptible patients.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphedema
Study phase:
Phase I
Physician name:
Simona Shaitelman
Department:
Radiation Oncology
For general questions about clinical trials:
1-833-731-1107
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.